RPRX

Royalty Pharma
D

RPRX

Arincen67/100B
67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
OverviewFinancialsForecastEarningsDividendsCompany

Royalty Pharma total debt 2015–2026

Royalty Pharma's total debt was 8.59B USD on 30 September 2026, down 4.2% on a year before. At the end of fiscal year 2025 it was 8.95B USD.

Last updated 6 Nov 2026 · Next report 10 Feb 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter30 Sept 20268.59B-4.22%544.86M-8.04B1.26
FY202531 Dec 20258.95B+17.58%637.50M-8.31B1.38
FY202431 Dec 20247.61B+24.08%1.77B-5.84B1.10
FY202331 Dec 20236.14B-13.79%1.23B-4.90B0.94
FY202231 Dec 20227.12B+0.29%2.43B-4.69B1.26
FY202131 Dec 20217.10B+22.00%2.80B-4.29B1.23
FY202031 Dec 20205.82B-6.76%2.65B-3.17B1.21
FY201931 Dec 20196.24B-4.31%793.21M-5.44B1.02
FY201831 Dec 20186.52B-4.15%2.39B-4.13B1.45
FY201731 Dec 20176.80B+15.34%1.38B-5.42B1.52
FY201631 Dec 20165.90B-1.52%1.67B-4.22B1.33
FY201531 Dec 20155.99B—1.72B-4.27B1.28

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Royalty Pharma's debt

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.